Media headlines about Verastem (NASDAQ:VSTM) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Verastem earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.8320963011857 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Knock at Technical analysis on Verastem, Inc. (VSTM) – Wall Street Morning (wallstreetmorning.com)
- Hot Stock in the Spotlight – Verastem, Inc. (NASDAQ: VSTM) – The Investor Guide (wallstreetnews24.com)
- Trending Hot Stock’s Analysis – Verastem Inc (NASDAQ: VSTM) – Alpha Beta Stock (alphabetastock.com)
- Head to Head Contrast: Verastem (VSTM) & Obseva (OBSV) (americanbankingnews.com)
- Verastem Inc (VSTM) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
Several analysts have commented on VSTM shares. Cann reaffirmed a “buy” rating and issued a $15.00 price objective (up previously from $6.00) on shares of Verastem in a research report on Sunday, December 10th. Cantor Fitzgerald set a $17.00 price objective on shares of Verastem and gave the stock a “buy” rating in a research report on Sunday, December 10th. Roth Capital started coverage on shares of Verastem in a research report on Friday, December 1st. They issued a “buy” rating and a $12.00 price objective on the stock. HC Wainwright set a $10.00 price objective on shares of Verastem and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Verastem in a research report on Monday, December 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $10.14.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.